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OBJECTIVES: Few studies in recent years, have evaluated the health related quality
of life (HRQoL) of patients with hyperparathyroidism (PHP) using validated instru-
ments. Only one specific questionnaire has been used to assess the HRQoL in these
patients but is more focused on the severity of associated symptoms than on the
impact of PHP on HRQoL. A new specific questionnaire to assess the HRQoL of
patients with PHP has been developed using a standardized methodology.
METHODS: The objective of the questionnaire is to capture all the relevant aspects;
a literature review and a meeting with five endocrinologist experts were carried
out. To assess the impact on HRQoL of symptoms related to PHP in this population,
a semi-structured interview of 24 PHP patients was carried out. From these inter-
views a group of items were identified. Each item was subsequently scored by the
group of experts, according to clarity, frequency and importance in order to per-
form a qualitative reduction of the items. The final items were edited in a ques-
tionnaire format and administered to a sample of 67 PHP patients. A factorial
analysis and a Rasch analysis were performed to obtain the final pilot question-
naire before initiating the validation study. RESULTS: After qualitative reduction,
34 items were obtained. Factor analysis identified two dimensions with a total
variance explained of 51.5%. Rash analysis was used to exclude those items with
inadequate adjustment (INFIT or OUTFIT1.30 and 0.70) or those which were
redundant. The resultant scale was composed of 16 items (the final questionnaire,
PHPQoL). CONCLUSIONS: PHPQoL questionnaire will allow, once the validation
phase is completed and the psychometric properties (validity, feasibility and re-
sponsiveness to change) are assessed, to learn more on the impact of PHP in usual
clinical practice and clinical studies.
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The diabetes disease entity is a serious threat to society, becoming already the
epidemic of the twenty-first century. It currently affects over 220 million people
worldwide. In many countries, including Poland, this incurable disease is one of the
biggest challenges for health care. OBJECTIVES: The aim of this study is to deter-
mine the place of pharmaceutical care for a diabetic patient in the current health
care system in Poland, to examine the need for actual implementation of such
initiatives and the possible benefits arising from them. METHODS: 1) The analysis
of the currently functioning system of care for diabetic patients, and 2) The study of
the quality of life of people with diabetes and their educational needs (carried out
through a questionnaire). RESULTS: Data from 59 people were analyzed (55.9%
men). The significant amount of surveyed diabetes patients (62,71%) declares, that
is covered by community pharmacy. The respondents when asked for some clari-
fication regarding their perception and definition of community pharmacy listed
elements that are not perceived as such by the theoretical scope of this kind of care.
Almost 95% of respondents claims, that the improved knowledge regarding diabe-
tes contributes to manage with the disease. More than 83% of respondents express
the willingness to explore in more depth their knowledge regarding the topic. The
average value of quality of life among population is 67,31 (with reference to EQ-VAS
scale). CONCLUSIONS: Polish health care system among diabetic patients is still on
the low level. Patients face many limitations when attempting to access the med-
ical benefits and they lack education in the topic. The need for the knowledge
extension and the belief in its efficacy are on a very high level. In spite of many
premises of implementation community pharmacy services in Poland, still the role
of pharmacists is in many cases omitted.
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Fixed-dose combinations of antihyperglycaemic therapies were developed to re-
duce pill burden and improve convenience and adherence in patients with type 2
diabetes (T2DM). OBJECTIVES: To quantify the relative importance of dosing
schedules to T2DM patients and to estimate patients’ willingness to pay (WTP) for
improvements in dosing schedules. METHODS: Participants were US patients (age
18 years) with T2DM who were on oral antihyperglycaemic therapy. Each patient
completed a web-enabled, conjoint survey that presented a series of 8 choice ques-
tions, each including a pair of hypothetical oral antihyperglycaemic therapy pro-
files. Each profile was defined by reductions in average glucose, daily-dosing sched-
ule, chance of mild-to-moderate stomach problems, frequency of hypoglycaemia,
weight change, incremental treatment-related risk of congestive heart failure
(CHF), and out-of-pocket cost. Choice questions were based on predetermined ex-
perimental design. Random-parameters logit was used to estimate the relative
importance of each attribute and to calculate patients’ WTP for improvements in
daily dosing. RESULTS:Of the 2080 patients invited to participate in the study, 1115
patients completed the survey. Over the ranges of attribute levels in the survey,
out-of-pocket cost was the most important attribute. The remaining attributes
were ranked in order of importance as: glucose control, hypoglycaemia, chance of
mild-to-moderate stomach problems, weight change, incremental chance of CHF,
and daily-dosing schedule. On average, patients were willing to pay $35.52 (95% CI:
25.65, 44.89) monthly to move from three pills twice daily to one pill twice daily.
Patients were willing to pay $30.72 (95% CI: 21.18, 40.05) monthly to move from
three pills twice daily to two pills once daily. CONCLUSIONS: Although less impor-
tant than other factors associated with oral antihyperglycaemic therapy, reducing
pill burden through reductions in the frequency of dosing or number of pills per
dose is of value to T2DM patients.
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OBJECTIVES: Approximately 60% of people with diabetes experience non-severe
hypoglycemic events, the most troubling of which are non-severe nocturnal events
(NSNHE). Unfortunately, little is known about the specific impacts of NSNHEs on
functioning, well-being and diabetes management. METHODS: Nine focus groups
were conducted in the US and Europe (France, Germany, UK). Transcriptions were
coded based on modified grounded theoretical approach and a theoretical model of
the impact of NSNHEs derived.RESULTS: Seventy-seven people participated: mean
age 46.5 (20 to 65), (26 type 1, 51 type 2), 66.2% on insulin with on average 4.1 (range
1-25) NSNHEs per month. Analysis generated domains of: symptoms, corrective
diabetes management actions taken, sleep disruption, social and work impacts.
Participants reported awakening with sweating, shaking, dizziness, odd dreams,
and vision disturbances. The majority of participants noted difficulty in returning
to sleep following the NSNHE and many did not return to sleep for the remainder of
the night. As a result, most participants reported feeling fatigue and being physi-
cally ill (e.g. headaches) the next day, negatively impacting a wide range of daily
activities. This impact lasted well into the next day and sometimes for as much as
48 hours. Corrective actions often included a reduction in insulin dose and in-
creased blood glucose monitoring in subsequent days. At work, participants re-
ported calling in sick, arriving late, concentration problems, or reduced effort. They
described canceling social event and coping with irritability that affected their
interactions with family and friends. Additionally, sleep quality of partners was
also disrupted due to the event. NSNHEs were considered by most to be more
frightening, dangerous and anxiety provoking than daytime events. Findings were
similar across all countries. CONCLUSIONS: NSNHEs have a significant negative
impact and require further study. Reducing their frequency may help improve
diabetes management and patient quality of life.
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OBJECTIVES: Globally the prevalence of diabetes is increasing and it is expected
that about 370 million people will live with the condition by 2030. Based on this
expectation the public awareness about this disease remains quite low. Diabetes
strongly affects the health-related quality of life (HRQOL) especially along with
co-morbidities and complications. The aim of this study was to examine the HRQoL
of diabetics living in temporary camps of flood affected compared to controls living
in similar conditions. METHODS: We conducted a cross-sectional survey in five
camps in a rural district of Sindh between August and October 2010. In total, 169
persons with diabetes and 136 age and sex matched controls living in the same
camps were randomly selected from these camps. World Health Organization
Quality of Life questionnaire (WHOQOL-BREF) was used to assess HRQoL. Four
domain scores (physical health, psychological, social relations and environment)
were compared for cases (diabetics) and controls (non-diabetics) and the impact of
socio-economic factors was evaluated in both groups. RESULTS: Overall, the mean
(SD) age of study subjects was 51(14.9) years. The mean duration of diabetes among
respondents was 7.74.1 years. All WHOQOL domains were strongly reduced in
diabetic patients as compared to controls, with strongest effects in physical health
(39 versus 78 points of the 0 – 100 score) and psychological domains (29 versus 71)
and weaker effects in social relationships (57 versus 69) and environment domains
(32 versus 41). The impact of diabetes on HRQoL was especially severe among
females and older subjects. Diabetics with low literacy levels had significantly
weaker effects (p0.001) on the different domains compared to educated subjects.
CONCLUSIONS: Based on these findings, a public health intervention and informa-
tion campaign is needed to be launched in the flood affected camps for regular
disease monitoring of persons with diabetes to prevent them from developing
co-morbidities and complications.
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OBJECTIVES: The aim of this study is to characterize the children and the adoles-
cents from Centro Hospitalar da Cova da Beira with Type 1 Diabetes Mellitus, to
understand better which factors influence the level of Health-related Quality of Life
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and the implications that this entails. METHODS: It is presented as a cross-sec-
tional research, drafted in a descriptive and analytical component of data. It is
based on the application of an anonymous questionnaire to these patients, which
consists of three parts: 1) socio-demografic, clinical and disease’s characterization
data; 2) Pediatric Quality of Life Inventory Version 4.0 – PedsQLTM 4.0 and 3) Dia-
betes Quality of Life questionnaire – DQOL. The data was analyzed using SPSSâ
software – version 17 and were considered significant at p-value 0,10. RESULTS:
In total, 17 (68%) children and adolescents between 11-18 years, with an average
number of years with disease of 6,29 years, participated in this study. The dimen-
sions of PedsQLTM 4.0 “Emotional Functioning” and the “School Functioning” and
the sub-scales of DQOL “Worries about Diabetes” and “Satisfaction with treatment”
imply worst results in Health-related Quality of Life. It is observed that the vari-
ables gender, location, school performance and employment status of mother and
father can influence the level of quality of life. Moreover, this level is more satis-
factory in the presence of records related to more appropriate Body Mass index,
fewer years of disease, lower values of glycated hemoglobin type A1c and lower
number of insulin injections per day.CONCLUSIONS: It is recognized that this work
offers a partial view of the disease, but contributes to understand some implicated
factors in its control and in the level of quality of life of diabetic children and
adolescents. It is recommended that such assessments should be made regularly,
within a multi-disciplinary team which should be responsible for monitoring these
patients
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OBJECTIVES: Following the introduction of the Quality and Outcomes Framework
(QOF) in the UK there has been an increase in the number of patients below-target
HbA1c levels (HbA1c7.5%) from 39.7% to 52.1% between 2006 and 2008. However,
a substantial number of patients with type 2 diabetes mellitus (T2DM) remain
poorly controlled. This study quantifies the effect of poorly controlled T2DM on the
average number of microvascular and macrovascular events. METHODS: The Car-
diff Type 2 Diabetes Model was initiated with cohort profiles consistent with cur-
rent UK clinical practice in patients newly diagnosed with T2DM. HbA1c treatment
effects were modelled to correspond with the intensive and conventional control
groups in the UKPDS over a 20-year time horizon assuming: 1) patients achieve and
maintain target control (“controlled”), and 2) patients fail to achieve target control
(“uncontrolled”) having HbA1c levels of 7.5-9.0%. Data from primary care (THIN)
were used to categorise the number of patients by HbA1c level in those on first-line
therapy or diet and exercise whose duration of diabetes was 2 years. RESULTS:
Data from THIN demonstrated that 50% of patients had HbA1c below 7%. Of the
remaining, 20%, 13%, 7% and 10% had HbA1c readings in the following ranges:
7-7.4%; 7.5-7.9; 8-8.4 and 8.5% respectively. Compared to those controlled sub-
jects, with an HbA1c 7%, the model predicts 92, 115, 138 and 162 excess macro-
vascular and microvascular complications in those in the 7-7.4%; 7.5-7.9; 8-8.4 and
 8.5% HbA1c groups respectively. CONCLUSIONS: Given current budgetary con-
straints, an ageing population, and increasing obesity, it is imperative that patients
with T2DM are optimally managed in routine clinical practice from the outset.
Failure to manage patients appropriately will have substantial implications for
both patients and the healthcare system.
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OBJECTIVES: To assess how general practitioners (GPs) in France adapt their anti-
diabetic therapeutic strategies among type 2 diabetes mellitus (T2DM) patients
who also had chronic kidney disease (CKD). METHODS: A multi-centric cross-sec-
tional and retrospective study was undertaken, investigating patient characteris-
tics, disease severity, therapeutic strategies, reasons for changes thereof through
questionnaires filled by GPs, coupled with drug treatments extracted from the IMS
Disease Analyser database. RESULTS: The study sample included 120 T2DM pa-
tients (median age  76.0, 45% men): 37 with stage 3a CKD (45GFR60 ml/min,
median age 75.1, 57% men) and 83 with stage 3b or severe CKD (GFR45 ml/min,
median age 76.4, 38% men). Oral anti-diabetic treatments were widely prescribed
among CKD patients: of those with stage 3a and 3b, respectively 37.5% and 39.3%
had oral monotherapy, while 40.6% and 28.6% had oral double or triple therapy.
21.9% and 32.1% had insulin therapy (3 a and 3 b, respectively). 65% of patients were
treated with an anti-diabetic drug which is either contraindicated or not recom-
mended for CKD patients; GPs adapted the anti-diabetic strategy during the previ-
ous year for 43% patients, 53% of the time due to CKD. Mean HbA1c was 7.1% and
7.2% among CKD stage 3a and 3b patients, respectively; with 58% (3a) and 54% (3b)
having HbA1c7. Only 23% of patients achieved control of diabetes (GP assess-
ment), with treatment that does not include a drug either contraindicated or not
recommended for this patient group; 2/3 of these patients received insulin.
CONCLUSIONS: Treating T2DM patients with CKD remains a challenge for GPs:
data suggest that GPs are favouring glycemic control over safety by using anti-
diabetic drugs that are either contraindicated or not recommended for CKD pa-
tients. New oral treatments that would allow physicians to control glycemia while
appropriately considering impaired renal function are needed.
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OBJECTIVES: To assess the causes for referral of type 2 diabetes (T2DM) patients
from primary care (PC) to specialized care (SC) in Spain. To assess the degree of
compliance with referral quality markers established in national
guidelines/recommendations. METHODS: Observational, cross-sectional, multi-
centre national study, in PC and SC. Each physician provided data on usual practice
for T2DM patient referral and clinical status of patients with T2DM for 6 referred
patients. Inclusion criteria for patients were: written consent, previous T2DM di-
agnosis and age over 18; exclusion criteria: T1DM, MODY, LADA and secondary
diabetes. Recommendations of the Spanish Society for Endocrinology and Nutri-
tion (SEEN) and the National Health System (SNS), were used as reference docu-
ments to assess compliance. RESULTS: Data from clinical practice of 143 endocri-
nologists and 641 general practitioners (GPs), and from referrals of 805 patients to
PC and 3624 to SC are presented. PC to SC referrals: 31.8% of GPs reported the
existence of a coordination protocol with endocrinologists. The most frequent
communication tool with SC was Consultation Report (89.2%). The referral criterion
that most GPs reported to apply in usual practice was Metabolic Instability (80.5%).
The most frequent cause for referral among the patients studied was Reassess-
ment (48.4%), a criterion not included in national guidelines. 46.8% of GPs applied in
usual practice all SNS, 3.9% all SEEN referral criteria. SC to PC referrals: 46.2% of
endocrinologists reported the existence of a coordination protocol with PC. The
most frequent communication channel with PC was Medical History (47.2%). The
referral criterion reported by a higher number of endocrinologists (96.5%) was Goal
Achievement, most frequent cause for referral also among the patients studied.
CONCLUSIONS:These findings emphasise the need of improving coordination pro-
cesses to optimize and homogenize referrals. The number of reported coordination
protocols is low, and the compliance with national guidelines poor.
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OBJECTIVES: To identify patient barriers, clinical management concerns, and drug
coverage issues for elderly type 2 diabetes patients in the Medicare Part D
population METHODS: A literature review was conducted using PubMed with
searches limited to studies published in the last 2 years, in English, and in aged 65.
Searches included combinations of the following terms: diabetes mellitus, mortal-
ity, prevention and control, Medicare, diabetes management, treatment guide-
lines, control. Hand searching of clinical management guidelines and diabetes
conferences (2007-present) was conducted to identify further issues pertaining to
the research questions of interest. RESULTS: The literature search by key word
yielded 141 relevant articles, 42 of which were included after abstract review for
relevance. Literature on clinical management challenges identified a high preva-
lence of untreated disease in this patient population due to a significantly large
number of elderly type 2 diabetes patients being undiagnosed. Adherence to treat-
ment guidelines in this patient population is challenging due to the high level of
co-morbidities that may complicate the goal of intensive glucose management. As
more oral antidiabetic agents become available as treatment options, patients be-
come more likely to change therapies with more elderly patients switching from
single-agent to combination therapy. Literature on cost-sharing in Medicare Part D
and the current coverage gap suggest that patients covered under the benefit face
a high out of pocket burden for treatment and that such costs lead to medication
non-adherence and physician switching to less efficacious alternatives
CONCLUSIONS: Clinical management challenges and economic barriers to access
are more pronounced for elderly Medicare Part D than in the general population of
type 2 diabetes patients. Further insight and research are needed to explore how
policy changes for coverage and treatment guidelines may be able to address these
concerns.
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OBJECTIVES: To describe demographic and clinical characteristics of diabetic pa-
tients who initiated basal insulin and assess their glycemic control. METHODS:
Physician encounters recorded in the General Electric EMR Database (2005-2010)
were assessed. Patients with type II diabetes (T2DM) who initiated basal insulin
between February 2006 and August 2009 were selected, with initiation defined as
no prescription record of insulin in prior 15 months. Patients were followed for an
average of 2.5 years after insulin initiation, and the proportion achieving A1C7%
(“goal”) and time to achieving goal were assessed. Among patients who reached
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